Hemogenyx
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
6 Heddon St, London, Greater London, W1B...Website
www.hemogenyx.comRevenue
<$5 MillionStock Symbol
HEMOIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Hemogenyx
For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx Pharmaceuticals plc's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation. Hemogenyx Pharmaceuticals plc is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. The Company is developing several distinct and complementarRead more
Hemogenyx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hemogenyx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Hemogenyx, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Hemogenyx is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Hemogenyx
Check if Hemogenyx has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Hemogenyx had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Hemogenyx has new funding data
Product Launch: Get notified when Hemogenyx launches new products
Earning: See what the market has to say on Hemogenyx recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Hemogenyx as Masked Content
Find 2 more new buyers
Compare Similar Companies to Hemogenyx
Compare insights from companies similar to Hemogenyx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Hemogenyx is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Hemogenyx is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Hemogenyx.
Hemogenyx financials insights
Gather financial insights about Hemogenyx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$13.2M
Hemogenyx Tech Stack
A closer look at the technologies used by Hemogenyx
See more technologies
Hemogenyx News & Media
Made Scientific and Hemogenyx Pharmaceuticals Announce Technology Transfer and Manufacturing Partnership to Advance HG-CT-1, an Autologous CAR-T Cell Therapy for Acute Myeloid Leukemia
PRINCETON, N.J. and NEW YORK, Sept. 8, 2025 /PRNewswire/ -- Made Scientific, a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical company developing targeted...Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT ...Hemogenyx Pharmaceuticals PLC Announces Issue of Convertible Loan Notes
LONDON, UK / ACCESS Newswire / February 19, 2025 / NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROMHemogenyx Pharmaceuticals PLC Announces Equity Incentive Pool Increase and Option Grant
Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that the Company's Board of Directors has resolved to increase the pool for the granting of share options, restricted shares, and restricted share units under the Company's 2021 Equity Incentive Plan with Non-Employee Sub-Plan by 60,000,000 shares, amounting to a total pool of 90,000,000 shares.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hemogenyx
Sign Up For FreeTo access detailed company insights
For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx Pharmaceuticals plc's technology has the pot... Read More
